• Worked with UK Levemir Product Manager (SCOU) developing existing campaign materials for use by the UK sales team – Once daily and Weight Selling Sheet, Weight Mailer to whole of primary care (56000).
• Identified regional sales differences in basal segment of the UK market to maximise regional opportunities to drive sales.
• Successfully set up and ran a regional pilot project, creating a variety of innovative initiatives promoting Levemir® in the region with the UK’s highest glargine market share. (Patient titration booklet, NNUK medical team meetings with KOLs, Great Weight Debate – large KOL speaker meeting - R130)
• Created and ran a successful advisory board which highlighted the potential for obtaining additional Levemir business through local pharmacist activity – to be applied to UK sales promotion 2008 (tbc)
• Developed the first UK Levemir E-detailing tool in order to complement and enhance Sales and Marketing initiatives for Levemir® in the UK.
Sales representative (12 months), Sales Effectiveness, FALA, France
Accountable and responsible for modern insulin sales in primary care and secondary care for territory L808.
Results: grew market share by (over national average market share growth)
• +10% Novomix® 30
• +6% for NovoRapid®
• +11% for Levemir®.
European Business Analyst, Commercial Department, ASEI, Switzerland
Elaborated new analytical reports and data support aiming to increase market dynamic understanding for European stakeholders (REMAN, SME team and top 8 affiliates). Trained two Business Analysts into this role (LFSC, SDLL):
• Sales performance benchmarking reports for top 8 countries
• P&L, market share, market growth, sales and capture rate analysis and forecasting
• IMS data analysis and forecasting using SAP and excel based models
• Sales and marketing effectiveness reporting
• Competitor intelligence reporting: NNRE Newsletter
